Skip to main content
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1992 Sep;85(9):530–533. doi: 10.1177/014107689208500907

Ceftazidime versus aminoglycoside and (ureido)penicillin combination in the empirical treatment of serious infection.

N Finer 1, P Goustas 1
PMCID: PMC1293638  PMID: 1433118

Abstract

Urgent treatment of serious infections with broad spectrum antibiotics usually starts before bacteriological evidence of the infective organism(s) becomes available. In this study 471 patients with a clinical diagnosis of sepsis were treated empirically with ceftazidime (CAZ) monotherapy (249 patients), or with an aminoglycoside+(ureido)penicillin combination (AG+PEN) (222 patients) to establish clinical outcome and bacteriological response. Up to 72 h post-treatment 94.5% of patients in the CAZ group and 93.8% in the AG+PEN group were treated successfully (treatment difference 0.7%, P < 0.01, 95% confidence interval -3.8%, 5.2%); 2-4 weeks after treatment neither regimen proved clinically superior. The differences in bacteriological response up to 72 h, and at 2-4 weeks after treatment, were 5.6% and 12.4% in favour of CAZ, however, these were not statistically significant. Overall, 56 patients reported 72 adverse events in the CAZ group, compared with 33 patients reporting 41 adverse events in the AG+PEN group. Deaths, 40 on CAZ and 21 on AG+PEN, were mainly related to their underlying condition. The two regimens were shown to be clinically equivalent in seriously ill patients treated empirically.

Full text

PDF
530

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alestig K., Eilard T., Norrby R., Svensson R., Trollfors B., Brorson J. E. Ceftazidime in clinical practice. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):111–114. doi: 10.1093/jac/12.suppl_a.111. [DOI] [PubMed] [Google Scholar]
  2. Kahlmeter G., Dahlager J. I. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984 Jan;13 (Suppl A):9–22. doi: 10.1093/jac/13.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  3. Malek M., Lynch W., Wells N., Elliott T., Bint A., Sanderson P., Jaderberg M., Davey P. A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals. J Antimicrob Chemother. 1992 Feb;29(2):207–217. doi: 10.1093/jac/29.2.207. [DOI] [PubMed] [Google Scholar]
  4. Parr M. D., Hansen L. A., Waite W. W., Rapp R. P. Computer program for comparing total costs of intravenous antibiotic regimens. Am J Hosp Pharm. 1986 Sep;43(9):2189–2193. [PubMed] [Google Scholar]
  5. Stoutenbeek C. P., van Saene H. K., Miranda D. R., Zandstra D. F., Binnendijk B. The prevention of superinfection in multiple trauma patients. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):203–211. doi: 10.1093/jac/14.suppl_b.203. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES